Literature DB >> 17260186

Sclareol induces apoptosis in human HCT116 colon cancer cells in vitro and suppression of HCT116 tumor growth in immunodeficient mice.

Konstantinos Dimas1, Sophia Hatziantoniou, Sophia Tseleni, Humaira Khan, Aristidis Georgopoulos, Konstantinos Alevizopoulos, James H Wyche, Panayotis Pantazis, Costas Demetzos.   

Abstract

Labd-14-ene-8, 13-diol (sclareol) is a labdane-type diterpene, which has demonstrated significant cytotoxic activity against human leukemic cell lines, but its effect on solid tumor-derived cells is uknown. Here, we demonstrate that addition of sclareol to cultures of human colon cancer HCT116 cells results in inhibition of DNA synthesis, arrest of cells at the G(1) phase of the cell cycle, activation of caspases-8, -9, PARP degradation, and DNA fragmentation, events characteristic of induction of apoptosis. Intraperitoneal (ip) administration of sclareol alone, at the maximum tolerated dose, was unable to induce suppression of growth of HCT116 tumors established as xenografts in immunodeficient SCID mice. In contrast, ip administration of liposome-encapsulated sclareol, following a specific schedule, induced suppression of tumor growth by arresting tumor cell proliferation as assessed by detecting the presence of the cell proliferation-associated nuclear protein, Ki67, in thin tumor sections. These findings suggest that sclareol incorporated into liposomes may possess chemotherapeutic potential for the treatment of colorectal and other types of human cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17260186     DOI: 10.1007/s10495-006-0026-8

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  8 in total

Review 1.  From serendipity to mitochondria-targeted nanocarriers.

Authors:  Volkmar Weissig
Journal:  Pharm Res       Date:  2011-08-11       Impact factor: 4.200

2.  In vitro activity of dietary flavonol congeners against human cancer cell lines.

Authors:  Chrisiida Tsimplouli; Costas Demetzos; Margarita Hadzopoulou-Cladaras; Panayotis Pantazis; Konstantinos Dimas
Journal:  Eur J Nutr       Date:  2011-05-20       Impact factor: 5.614

3.  Inhibition of angiogenesis- and inflammation-inducing factors in human colon cancer cells in vitro and in ovo by free and nanoparticle-encapsulated redox dye, DCPIP.

Authors:  Fadee G Mondalek; Sivapriya Ponnurangam; Janita Govind; Courtney Houchen; Shrikant Anant; Panayotis Pantazis; Rama P Ramanujam
Journal:  J Nanobiotechnology       Date:  2010-07-15       Impact factor: 10.435

4.  Sclareol inhibits RANKL-induced osteoclastogenesis and promotes osteoblastogenesis through promoting CCN1 expression via repressing the MAPK pathway.

Authors:  Xiang Li; Yuxin Wang; Liangping Li; Shengji Zhou; Fengchao Zhao
Journal:  Cell Biol Toxicol       Date:  2021-01-09       Impact factor: 6.691

5.  Sclareol inhibits cell proliferation and sensitizes cells to the antiproliferative effect of bortezomib via upregulating the tumor suppressor caveolin-1 in cervical cancer cells.

Authors:  Ting Zhang; Ting Wang; Peiling Cai
Journal:  Mol Med Rep       Date:  2017-04-13       Impact factor: 2.952

Review 6.  Advances on Natural Abietane, Labdane and Clerodane Diterpenes as Anti-Cancer Agents: Sources and Mechanisms of Action.

Authors:  Rosaria Acquaviva; Giuseppe A Malfa; Monica R Loizzo; Jianbo Xiao; Simone Bianchi; Rosa Tundis
Journal:  Molecules       Date:  2022-07-26       Impact factor: 4.927

Review 7.  The bioactivities of sclareol: A mini review.

Authors:  Jianbo Zhou; Xiaofang Xie; Hailin Tang; Cheng Peng; Fu Peng
Journal:  Front Pharmacol       Date:  2022-10-03       Impact factor: 5.988

8.  Functional membrane androgen receptors in colon tumors trigger pro-apoptotic responses in vitro and reduce drastically tumor incidence in vivo.

Authors:  Shuchen Gu; Natalia Papadopoulou; Eva-Maria Gehring; Omaima Nasir; Konstantinos Dimas; Shefalee K Bhavsar; Michael Föller; Konstantinos Alevizopoulos; Florian Lang; Christos Stournaras
Journal:  Mol Cancer       Date:  2009-12-01       Impact factor: 27.401

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.